<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Inform</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Inform</journal-id><journal-id journal-id-type="publisher-id">Cancer Informatics</journal-id><journal-title-group><journal-title>Cancer Informatics</journal-title></journal-title-group><issn pub-type="epub">1176-9351</issn><publisher><publisher-name>Libertas Academica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4874744</article-id><article-id pub-id-type="doi">10.4137/CIN.S34141</article-id><article-id pub-id-type="publisher-id">cin-15-2016-091</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Bioinformatic Studies to Predict MicroRNAs with the Potential of Uncoupling RECK Expression from Epithelial&#8211;Mesenchymal Transition in Cancer Cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhipeng</given-names></name><xref ref-type="aff" rid="af1-cin-15-2016-091">1</xref><xref ref-type="corresp" rid="c1-cin-15-2016-091"/></contrib><contrib contrib-type="author"><name><surname>Murakami</surname><given-names>Ryusuke</given-names></name><xref ref-type="aff" rid="af2-cin-15-2016-091">2</xref></contrib><contrib contrib-type="author"><name><surname>Yuki</surname><given-names>Kanako</given-names></name><xref ref-type="aff" rid="af1-cin-15-2016-091">1</xref></contrib><contrib contrib-type="author"><name><surname>Yoshida</surname><given-names>Yoko</given-names></name><xref ref-type="aff" rid="af1-cin-15-2016-091">1</xref></contrib><contrib contrib-type="author"><name><surname>Noda</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="af1-cin-15-2016-091">1</xref><xref ref-type="aff" rid="af3-cin-15-2016-091">3</xref><xref ref-type="corresp" rid="c1-cin-15-2016-091"/></contrib></contrib-group><aff id="af1-cin-15-2016-091"><label>1</label>Laboratory for Malignancy Control Research, Medical Innovation Center, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</aff><aff id="af2-cin-15-2016-091"><label>2</label>Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</aff><aff id="af3-cin-15-2016-091"><label>3</label>Department of Molecular Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.</aff><author-notes><corresp id="c1-cin-15-2016-091">CORRESPONDENCE: <email>mnoda@virus.kyoto-u.ac.jp</email>; <email>wangz@kuhp.kyoto-u.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>19</day><month>5</month><year>2016</year></pub-date><volume>15</volume><fpage>91</fpage><lpage>102</lpage><history><date date-type="received"><day>04</day><month>9</month><year>2015</year></date><date date-type="rev-recd"><day>24</day><month>2</month><year>2016</year></date><date date-type="accepted"><day>07</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>&#169; 2016 the author(s), publisher and licensee Libertas Academica Ltd.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.</license-p></license></permissions><abstract><p>RECK is downregulated in many tumors, and forced <italic>RECK</italic> expression in tumor cells often results in suppression of malignant phenotypes. Recent findings suggest that RECK is upregulated after epithelial-mesenchymal transition (EMT) in normal epithelium-derived cells but not in cancer cells. Since several microRNAs (miRs) are known to target <italic>RECK</italic> mRNA, we hypothesized that certain miR(s) may be involved in this suppression of RECK upregulation after EMT in cancer cells. To test this hypothesis, we used three approaches: (1) text mining to find miRs relevant to EMT in cancer cells, (2) predicting miR targets using four algorithms, and (3) comparing miR-seq data and <italic>RECK</italic> mRNA data using a novel non-parametric method. These approaches identified the miR-183-96-182 cluster as a strong candidate. We also looked for transcription factors and signaling molecules that may promote cancer EMT, miR-183-96-182 upregulation, and RECK downregulation. Here we describe our methods, findings, and a testable hypothesis on how RECK expression could be regulated in cancer cells after EMT.</p></abstract><kwd-group><kwd>cancer</kwd><kwd>EMT</kwd><kwd>RECK</kwd><kwd>paired data correlation</kwd><kwd>miR-183-96-182</kwd><kwd>SOX2</kwd><kwd>TEAD4</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>RECK is downregulated in many types of tumors. Forced expression of RECK inhibits tumor angiogenesis, invasion, metastasis, and/or proliferation, depending on the cell system.<xref rid="b1-cin-15-2016-091" ref-type="bibr">1</xref>&#8211;<xref rid="b5-cin-15-2016-091" ref-type="bibr">5</xref> However, the molecular mechanisms of RECK downregulation in tumor cells remain largely unknown.</p><p>The epithelial&#8211;mesenchymal transition (EMT) is a process by which epithelial cells lose their apicobasal polarity and cell&#8211;cell adhesion and gain migratory and invasive properties, resembling those of mesenchymal cells. EMT is essential for numerous developmental processes, including mesoderm formation and neural tube formation. EMT has also been shown to occur during wound healing, organ fibrosis, cancer invasion, and metastasis.<xref rid="b6-cin-15-2016-091" ref-type="bibr">6</xref>,<xref rid="b7-cin-15-2016-091" ref-type="bibr">7</xref></p><p>Accumulating evidence indicates the involvement of a number of microRNAs (miRs) in the process of carcinogenesis, as well as cancer progression.<xref rid="b8-cin-15-2016-091" ref-type="bibr">8</xref> Based on their activities, cancer-associated miRs can be divided into two groups: oncomiRs and tumor suppressor miRs. A single miR may target multiple mRNAs, while one mRNA may be targeted by multiple miRs, providing a basis for an intricate network of gene regulation. Hence, bioinformatic analyses and evaluation of large sets of data and publications already accumulated in this field of studies should be a reasonable approach for deducing the cellular functions of miRs. For example, numerous papers on miRs relevant to EMT as well as miRs induced by various stimuli (such as hypoxia and growth factors) and targeting <italic>RECK</italic> mRNA have already been published (see below).</p><p>We previously found that TGF&#946;-induced EMT was accompanied by RECK upregulation in nontumorigenic epithelial cell lines (MCF10A and HMLE), but not in carcinoma- derived cell lines (MCF7 and A549).<xref rid="b9-cin-15-2016-091" ref-type="bibr">9</xref><italic>RECK</italic> overexpression did not affect the process of EMT but negatively regulated cell proliferation and migration. Although the exact mechanisms by which RECK expression is uncoupled from EMT in cancer cells remain to be elucidated, one obvious possibility is transcriptional repression of <italic>RECK</italic> gene in cancer cells. However, we found some discrepancy between the levels of <italic>RECK</italic> mRNA and RECK protein in cancer cells and, therefore, speculated whether some cancer-associated miRs might also play roles in this uncoupling. To address this question in this study, we first attempted to find candidate miRs using three approaches <italic>in silico</italic>: (1) text mining to extract miRs enriched in studies of cancer EMT, (2) prediction of miRs targeting <italic>RECK</italic> mRNA, and (3) analysis of TCGA breast cancer miR-seq and <italic>RECK</italic> mRNA data using a newly developed nonparametric correlation test. These approaches point to the involvement of the miR-183-96-182 cluster in the uncoupling of RECK expression from EMT in cancer cells. We also searched for candidate transcription factors involved in this event using ENCODE, transcription factor ChIP-seq data, ONCOMINE gene expression database, and expression datasets deposited in NCBI GEO. We propose a testable hypothesis based on these findings.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Collecting relevant abstracts from PubMed</title><p>The following sets of key words were used to collect relevant abstracts of original papers from PubMed: for EMT-associated miRs in noncancerous cells, (microRNA[Title/Abstract] OR miRNA[Title/Abstract] OR miR[Title/Abstract]) AND (EMT[Title/Abstract] OR &#8220;epithelial-mesenchymal transition&#8221;[Title/Abstract] OR &#8220;epithelial-to-mesenchymal&#8221;[Title/Abstract]) NOT (cancer[Title/Abstract] OR metastasis[Title/Abstract] OR carcinoma[Title/Abstract] OR sarcoma[Title/Abstract] OR tumor[Title/Abstract] OR &#8220;review&#8221;[Publication Type]) and for EMT-associated miRs in cancer, (microRNA[Title/Abstract] OR miRNA[Title/Abstract] OR miR[Title/Abstract]) AND (EMT[Title/Abstract] OR &#8220;epithelial-mesenchymal transition&#8221;[Title/Abstract] OR &#8220;epithelial-to-mesenchymal&#8221;[Title/Abstract]) AND (cancer[Title/Abstract] OR metastasis[Title/Abstract] OR carcinoma[Title/Abstract] OR sarcoma[Title/Abstract] OR tumor[Title/Abstract]) NOT &#8220;review&#8221;[Publication Type]. The search was performed on November 2, 2015. The abstracts were downloaded as .txt files.</p></sec><sec><title>Text mining for miRs with differences between noncancerous and cancer cells</title><p>We used R package &#8220;pubmed. mineR&#8221;<xref rid="b10-cin-15-2016-091" ref-type="bibr">10</xref> to process the abstracts from PubMed. This provided a correspondence table &#8220;HGNCdata&#8221; that includes approved symbol, approved name, gene synonyms, and so on for genes, but not for miRs. Therefore, we acquired miR-related information from the HUGO Gene Nomenclature Committee (HGNC) website.<xref rid="b11-cin-15-2016-091" ref-type="bibr">11</xref> In the abstracts, several alias/synonyms are used to describe the same miR. Thus, we first mapped the prefix &#8220;miR-&#8221;, &#8220;microRNA-&#8221;, &#8220;MicroRNA-&#8221;, &#8220;hsa-miR-&#8221;, and &#8220;mmu-miR-&#8221; to the same character &#8220;MIR&#8221;, converting the alias in the abstract to the approved symbol, according to HGNC. The converted abstracts were analyzed using pubmed.mineR; we first used the gene_atomization function to extract the miRs mentioned in the abstracts and then used the searchabsT function to count the abstracts that referred to each miR. For each miR referred, we calculated its proportion to all papers describing cancer EMT or noncancer EMT and tested the null hypothesis that the proportion in cancer EMT = proportion in noncancer EMT using two-tailed prop.test.</p></sec><sec><title>Prediction of miR targets</title><p>We used four commonly used tools for predicting miRs: miRanda (August 2010 release),<xref rid="b12-cin-15-2016-091" ref-type="bibr">12</xref>,<xref rid="b13-cin-15-2016-091" ref-type="bibr">13</xref> PicTar,<xref rid="b14-cin-15-2016-091" ref-type="bibr">14</xref> TargetScan,<xref rid="b15-cin-15-2016-091" ref-type="bibr">15</xref>&#8211;<xref rid="b17-cin-15-2016-091" ref-type="bibr">17</xref> and MicroT-CDS (microT v4).<xref rid="b18-cin-15-2016-091" ref-type="bibr">18</xref> For miRanda, we used human target site predictions with good mirSVR score and conserved miR. PicTar predictions in vertebrates were used with the default setting to search for all miRs potentially targeting <italic>RECK</italic>, and to evaluate them based on the PicTar score. TargetScan was used with the default setting, and the Context score and <italic>P</italic><sub>CT</sub> (probability of conserved targeting) were used to evaluate the probability of a miR to bind <italic>RECK</italic> 3&#8242;-UTR. For microT-CDS, we used the gene symbol &#8220;RECK&#8221;, gene ID &#8220;ENSG00000122707&#8221;, species &#8220;Homo sapiens&#8221;, and Ensembl version 69 from homologous genes. The results were evaluated using the miTG score.</p></sec><sec sec-type="methods"><title>Data collection from TCGA</title><p>We acquired the breast invasive carcinoma dataset from the TCGA website<xref rid="b19-cin-15-2016-091" ref-type="bibr">19</xref> on May 3, 2013. From the total 905 breast cancer cases, we extracted 53 cases for which mRNA and miR data on both cancer tissues and matched normal breast tissues were available. In the TCGA project, mRNA expression data had been acquired using Agilent 244K Custom Gene Expression G4502A-07 platform (alias: AgilentG4502A_07). miR-seq data had been obtained using Illumina Genome Analyzer (alias: illuminaga) system or Illumina Hiseq (alias: illuminahiseq) system. For miR-seq analysis, we used the level 3 data (ie, expression calls for miRs per sample). In the case of mRNA, we used level 2 data (ie, normalized signals per probe) and averaged the expression calls of the probes that correspond to the same gene to obtain a single value for each gene. Agilent G4502A_07 contains five probes for <italic>RECK</italic>. From them, we chose to use two (A_23_P83028 and A_23_P83030) that were corresponding to the 3&#8242;-UTR of the full-length <italic>RECK</italic> transcript; the other three probes were ignored in this study, since they may also pick up smaller transcripts whose functions are presently unclear (<xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Fig. 1</xref>). To avoid division by zero in calculation, we assigned the uniform value of 0.1 to all cases in which the miR expression was undetectable.</p></sec><sec sec-type="methods"><title>The paired data correlation test</title><p>To facilitate evaluation of the trends in expression changes, we developed a nonparametric method as follows: by setting appropriate cutoff values, the expression change between a pair of measurements was categorized into three groups (up, down, and no change) and labeled accordingly (1, &#8722;1, and 0, respectively). We call this label &#8220;Value of Change&#8221;. To compare the changes in two factors (eg, a miR vs. <italic>RECK</italic> mRNA), the absolute value of the difference between two Values of Changes was used for evaluation; we call this parameter &#8220;diff&#8221;. Thus, diff = 0 indicates two factors changing toward the same direction, diff = 1 indicates no change in one factor and up or down in the other, and diff = 2 indicates two factors changing toward the opposite directions. To evaluate the trends of changes in multiple pairs of data (eg, multiple patients), the sum of diff (termed &#8220;diff.sum&#8221; score) was used. In this case, a smaller diff.sum score indicates a trend of two factors changing toward the same direction, whereas a larger diff.sum score indicates a trend of two factors changing toward opposite directions. The <italic>P</italic>-value for each diff.sum score was calculated by simulation to evaluate how likely the diff.sum score can be obtained by chance. Specifically, we first got a vector containing 53 diff values for <italic>RECK</italic> mRNA and a 1046 &#215; 53 matrix containing diff values for 1046 miRs in 53 patients. We then simulated a 1000 times larger matrix, 1,046,000 &#215; 53, by randomly shufling the position of patients in the original diff matrix for miRs, while keeping the <italic>RECK</italic> diff vector unchanged. Using the <italic>RECK</italic> diff vector and the simulated diff matrix for miRs, we obtained 1,046,000 diff.sum scores. Probabilities for each specific diff.sum were then calculated based on the distribution of the 1,046,000 diff.sum scores. The concept of this nonparametric correlation test for paired data, which we termed the paired data correlation (PDC) test, is illustrated in <xref ref-type="fig" rid="f1-cin-15-2016-091">Figure 1</xref>. Based on the distribution of <italic>RECK</italic> mRNA and miRs in cancer and normal breast tissues, we chose cutoff values of 0.8 and 1.25 (&#177;0.3219 in log<sub>2</sub>), respectively, for the downregulation and upregulation of <italic>RECK</italic> mRNA, respectively, and 0.5 and 2.0 (&#177;1 in log<sub>2</sub>) for those of miRs.</p></sec><sec sec-type="methods"><title>Analysis of the miR-183-96-182 promoter</title><p>UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly<xref rid="b20-cin-15-2016-091" ref-type="bibr">20</xref> was used to search for possible transcription factors of the miR-183-96-182 cluster. Based on the tracks related to regulation (eg, Integrated Regulation from ENCODE Tracks)<xref rid="b21-cin-15-2016-091" ref-type="bibr">21</xref> and the position of transcription start site (TSS) of the miR-183-96-183 cluster, we decided to focus on the region up to 16 kb upstream of the miR-183 precursor. Transcription factors suggested to bind this region by the Transcription Factor ChIP-seq (161 factors) from ENCODE with Factorbook Motifs were extracted manually.</p></sec><sec sec-type="methods"><title>Survey of gene expression profile data</title><p>We screened gene expression profile data from knockdown, knockout, overexpression, or inhibitor treatment experiments relevant to candidate transcription factors. The NCBI GEO datasets that include information on miR-183-96-182 cluster were based mainly on three platforms, namely, Illumina HumanHT-12 V4.0 expression beadchip (GPL10558), Affymetrix Mouse Gene 1.0 ST Array (GPL6246), and Affymetrix Human Gene 1.0 ST Array (GPL6244). These data were acquired using R package &#8220;GEOquery&#8221;,<xref rid="b22-cin-15-2016-091" ref-type="bibr">22</xref> and the values for multiple probes corresponding to the same gene ID were averaged to obtain a representative value for each gene. For important candidates, we extended our search to other array-based platforms as well as RNA-seq data. We also used ONCOMINE 4.5<xref rid="b23-cin-15-2016-091" ref-type="bibr">23</xref> to find the trends in expression of candidate transcription factors for miR-183-96-182 in various cancers. The thresholds used were <italic>P</italic>-value = 0.001, fold change = 2, and gene rank = top 10%.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Text mining for papers describing miRs involved in cancer EMT and noncancer EMT</title><p>To examine our hypothesis that miRs may play roles in uncoupling RECK expression from EMT in cancer, we first surveyed original papers in PubMed describing miRs involved in cancer EMT and noncancer EMT using the key word sets described in the &#8220;Methods&#8221; section. This literature search yielded 887 papers on cancer EMT and 145 papers on noncancer EMT. The most reported miRs in cancer EMT were members of the miR-200 family: miR-200c (121 papers), miR-200b (75 papers), and miR-200a (59 papers). The most reported miR in noncancer EMT was miR-21 (20 papers), which has also been associated with cancer EMT (53 papers). Some miRs have only been associated with cancer EMT. For example, miR-22 has been associated with cancer EMT in 25 papers, but never with noncancer EMT. In total, 40 miRs have been associated with cancer EMT in more than three papers but never with noncancer EMT (<xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Table 1</xref>), although the specificity of association was statistically significant only in a few cases (probably because of the paucity of noncancer studies). Representative miRs are shown in <xref ref-type="table" rid="t1-cin-15-2016-091">Table 1</xref>.</p></sec><sec><title>Target prediction implicates miR-182 in uncoupling of RECK expression from EMT in cancer</title><p>Second, we screened for miRs potentially targeting <italic>RECK</italic> mRNA using four algorithms as follows: miRanda, TargetScan, PicTar, and DIANA-microT. These algorithms evaluate the following features in different combinations and emphases: (1) base pairing pattern between a miR and a possible target, (2) thermodynamic stability of miR-mRNA hybrid, and (3) conservation of target sequences across related species. Despite the differences in their theoretical bases and computational procedures,<xref rid="b24-cin-15-2016-091" ref-type="bibr">24</xref> the results from these four algorithms showed considerable overlap. Among the 16 miRs with an mirSVR score (miRanda) less than &#8722;1.2, 6 miRs were also detected with the other algorithms (<xref ref-type="table" rid="t2-cin-15-2016-091">Table 2</xref>). Of note, miR-182 gave the top score with miRanda (mirSVR) and high scores with Pictar (PicTar score), TargetScan (Context score and <italic>P</italic><sub>CT</sub>), and MicroT-CDS (miTG score; <xref ref-type="table" rid="t2-cin-15-2016-091">Table 2</xref> and <xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Tables 2</xref><xref ref-type="supplementary-material" rid="s1-cin-15-2016-091"/><xref ref-type="supplementary-material" rid="s1-cin-15-2016-091"/>&#8211;<xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">5</xref>).</p></sec><sec><title>Inverse correlation between the levels of miR-182 and <italic>RECK</italic> mRNA in breast cancer tissues</title><p>Third, we looked for miRs that show differential expression between cancer and normal tissues with correlation to <italic>RECK</italic> mRNA expression levels. For this purpose, we chose to use TCGA breast cancer data in which both mRNA and miR data in cancer tissues as well as matched normal tissues were available (<italic>n</italic> = 53). As expected, highly significant downregulation of <italic>RECK</italic> mRNA in cancer tissues was observed (<italic>P</italic> = 0.000; <xref ref-type="fig" rid="f2-cin-15-2016-091">Fig. 2A</xref>). When we chose the cutoff values of 0.8 and 1.25 for downregulation and upregulation, respectively, we found that <italic>RECK</italic> mRNA was downregulated in cancer tissue in 47 patients, upregulated in two patients, and unchanged in four patients (<xref ref-type="fig" rid="f2-cin-15-2016-091">Fig. 2B</xref>).</p><p>In the case of miRs, distribution of the median of the ratio (cancer/normal) was roughly symmetrical around zero (in logarithmic scale). When cutoff values of 0.5 and 2 were chosen, 71 miRs were downregulated and 77 miRs were upregulated in cancer tissues (<xref ref-type="fig" rid="f2-cin-15-2016-091">Fig. 2C</xref>). For a technical reason (to avoid division by zero), we assigned the expression value of 0.1 to all undetectable miRs. Therefore, the miRs undetectable in both cancer and normal tissues would give the ratio of 1. Among the 638 miRs that gave the ratio of 1 (0 in the log<sub>2</sub> scale as shown in <xref ref-type="fig" rid="f2-cin-15-2016-091">Fig. 2C</xref>), 279 miRs were undetectable in all samples.</p><p>Based on these classifications, we compared the changes in the expression of <italic>RECK</italic> mRNA and miRs between cancer tissues and matched normal tissues using a newly developed nonparametric correlation test, named the PDC test (see &#8220;Methods&#8221; section for detail; the distribution of diff.sum based on simulation is illustrated in <xref ref-type="fig" rid="f2-cin-15-2016-091">Fig. 2D</xref>). Through this method, we obtained a list of 1046 miRs, whose expression is similarly or inversely correlated with that of <italic>RECK</italic> mRNA (<xref ref-type="table" rid="t3-cin-15-2016-091">Table 3</xref>; for full list, see <xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Table 6</xref>). In these tables, &#8220;diff.sum&#8221; score represents the extent of inverse correlation between the levels of the miR and <italic>RECK</italic> mRNA. In the present comparison of 53 pairs of data, diff.sum scores, by definition, range between 0 (perfect positive correlation) and 106 (perfect inverse correlation). The diff.sum scores for miR-139 (9) and miR-486-1 (13) are among the lowest in the list (<xref ref-type="table" rid="t3-cin-15-2016-091">Table 3</xref>, see also <xref ref-type="fig" rid="f2-cin-15-2016-091">Fig. 2E</xref>), indicating that the changes in their expression are concordant to that of <italic>RECK</italic> mRNA in most cases. Interestingly, both miRs have been reported as tumor suppressors, and their expression has been shown to be inversely correlated with tumor proliferation or progression.<xref rid="b25-cin-15-2016-091" ref-type="bibr">25</xref>,<xref rid="b26-cin-15-2016-091" ref-type="bibr">26</xref> On the other hand, the diff.sum scores for miR-96 (91) and miR-183 (95) are among the highest in the list, indicating their inverse correlation with <italic>RECK</italic> mRNA. miR-183, miR-96, and miR-182 are located in close proximity on human chromosome 7 and are expressed in a single primary transcript.<xref rid="b27-cin-15-2016-091" ref-type="bibr">27</xref> Indeed, miR-182 also shows a high diff.sum score (90). Of note, several well-studied miRs reported to exhibit oncogenic activities, such as miR-21, or those of bidirectional activities, such as the miR-200 family (miR- 200a, miR-200b, and miR-200c), are also among the high diff.sum score group (ie, inversely correlated with <italic>RECK</italic> mRNA).</p></sec><sec><title>TEAD4 and SOX2 as possible miR-183-96-182 regulators</title><p>The above findings prompted us to focus on the miR-183-96-182 cluster. Besides its inverse correlation in expression with <italic>RECK</italic> (<xref ref-type="table" rid="t3-cin-15-2016-091">Table 3</xref>), two of its members (miR-182 and miR-96) have the potential to target <italic>RECK</italic> (<xref ref-type="table" rid="t2-cin-15-2016-091">Table 2</xref>) and at least four studies have been published for each member (15 papers in total) in the context of cancer EMT, but never in the context of noncancer EMT (<xref ref-type="table" rid="t1-cin-15-2016-091">Table 1</xref>).</p><p>The TSS of the miR-183-96-182 primary transcript has been predicted to be at 5207 bp upstream of the miR-183 precursor on human chromosome 7.<xref rid="b28-cin-15-2016-091" ref-type="bibr">28</xref> A region of 4 kb surrounding this TSS is rich in nucleosomes with H3K4Me3 and H3K27Ac modifications, both known to mark active transcription. ENCODE ChIP-seq data also indicate binding of many (&#8764;70) transcription factors within the region of about 16 kb surrounding the TSS (<xref ref-type="fig" rid="f3-cin-15-2016-091">Fig. 3A</xref>). A survey of gene expression databases indicated that several of these factors may affect the expression of <italic>RECK</italic> in various experimental settings. For instance, knockdown of TEAD4 resulted in elevated <italic>Reck</italic> expression in the mouse myogenic cell line C2C12 (GSE27845, <xref ref-type="fig" rid="f3-cin-15-2016-091">Fig. 3B</xref>). Likewise, suppression of Ezh2 resulted in elevated <italic>Reck</italic> expression in high-grade glioma and preadipocytes (GSE63853 and GSE20054, respectively, <xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Fig. 5A and B</xref>). No miR-183-96-182 expression data are available from these experiments. Paradoxically, however, knockdown of EZH2 resulted in elevated expression of miR-183, miR-182, and miR-182* in the prostate cancer cell line DU145 (GSE26996, <xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Fig. 5C</xref>). No <italic>RECK</italic> expression data are available from this experiment.</p><p>We also surveyed the effects of additional 30 factors, mainly oncogenes and EMT regulators, on <italic>RECK</italic> and miR-183-96-182 expression. This survey detected SOX2, whose knockdown influenced the expression of the miR-183-96-182 cluster and <italic>RECK</italic>. In one dataset (GSE67993), SOX2 knockdown in human embryonic stem cells resulted in downregulation of miR-182/miR-96 and upregulation of <italic>RECK</italic> mRNA (<xref ref-type="fig" rid="f3-cin-15-2016-091">Fig. 3C</xref>). In another dataset (GSE49403), knockdown of SOX2 or its coregulator <italic>RMST</italic> in neural stem cells resulted in upregulation of <italic>RECK</italic> mRNA (<xref ref-type="fig" rid="f3-cin-15-2016-091">Fig. 3D</xref>), although this dataset did not provide information on miR-183-96-182 expression. In addition, another dataset (GSE59380) indicated that knockdown of SOX2 in the embryonal carcinoma cell line 2102Ep resulted in downregulation of miR-183/miR-182.<xref rid="b29-cin-15-2016-091" ref-type="bibr">29</xref></p></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec sec-type="methods"><title>Utility of the PDC test developed in this study</title><p>One of the questions we attempted to address in this study was when the level of <italic>RECK</italic> mRNA changes (between cancer and normal tissues), how the levels of various miRs change in the same patient. The change in this case can be qualitative, since it involves intrinsic differences between cancer tissue and the corresponding normal tissue. Our PDC test is a simple approach to make such comparisons possible. In this test, we can choose cutoff values depending on the nature of the data being compared. For example, the levels of <italic>RECK</italic> mRNA are known to be generally low among cancer samples, and therefore, a too strict cutoff value (eg, 0.5) for downregulation may cause unnecessary loss of information. In the case of miRs, however, more robust cutoff values of 0.5 should be more appropriate in light of their mechanism of action. However, even when we chose more stringent conditions (cutoff values of 0.5 and 2 for both <italic>RECK</italic> mRNA and miRs), the top five miRs detected in this study were the same, albeit in different order, demonstrating the robustness of this method. Nevertheless, the adjustability of cutoff values should make this method useful in wider applications.</p><p>In this study, the PDC test was successfully used for enriching miRs, whose expression are positively or inversely correlated with <italic>RECK</italic> expression. Of note, among the top 14 miRs with positive correlation with <italic>RECK</italic> mRNA (diff.sum &#8804;17, <italic>P</italic> &#8804; 0.013; <xref ref-type="table" rid="t3-cin-15-2016-091">Table 3</xref>, Ranking T1&#8211;T10), 12 miRs have previously been reported to have tumor suppressor function (<xref ref-type="table" rid="t3-cin-15-2016-091">Table 3</xref>). Among the top 11 miRs with inverse correlation with <italic>RECK</italic> mRNA (diff.sum &#8805;85, <italic>P</italic> &#8805; 0.991; <xref ref-type="table" rid="t3-cin-15-2016-091">Table 3</xref>, Ranking B1&#8211;B8), 6 miRs have previously been reported as oncomiRs, and importantly, 4 of them (miR-96,<xref rid="b30-cin-15-2016-091" ref-type="bibr">30</xref>&#8211;<xref rid="b32-cin-15-2016-091" ref-type="bibr">32</xref> miR-21,<xref rid="b33-cin-15-2016-091" ref-type="bibr">33</xref>&#8211;<xref rid="b36-cin-15-2016-091" ref-type="bibr">36</xref> miR-182,<xref rid="b37-cin-15-2016-091" ref-type="bibr">37</xref>&#8211;<xref rid="b39-cin-15-2016-091" ref-type="bibr">39</xref> and miR-92b<xref rid="b40-cin-15-2016-091" ref-type="bibr">40</xref>) target <italic>RECK</italic> directly. Furthermore, additional three miRs reported to target <italic>RECK</italic> mRNA (miR-7-1,<xref rid="b36-cin-15-2016-091" ref-type="bibr">36</xref> miR-200b,<xref rid="b41-cin-15-2016-091" ref-type="bibr">41</xref> and miR-200c<xref rid="b41-cin-15-2016-091" ref-type="bibr">41</xref>) are also found within the top 41 in this category. Hence, this approach seems to be useful for predicting potential oncomiRs and tumor suppressor miRs and, in more general, for predicting potential miR-target relationship.</p><p>Classical theory holds that miRs repress target gene expression through two mechanisms as follows: (1) perfect or nearly perfect base pairing with the target mRNA promotes cleavage of the mRNA and (2) partially complementary miRs inhibit translation of target mRNAs. However, more recent findings indicate that translational inhibition by partially complementary miRs is also accompanied by accelerated degradation of target mRNA.<xref rid="b42-cin-15-2016-091" ref-type="bibr">42</xref> Our approach (to find miRs that target <italic>RECK</italic> and show inverse correlation in expression with <italic>RECK</italic>) is based on this new understanding.</p></sec><sec><title>miR-183-96-182 may uncouple RECK expression from EMT in cancer</title><p>We used three approaches to find candidate miRs that play roles in RECK suppression after EMT in cancer cells. The first approach of surveying published reports in PubMed has an advantage that these findings have been experimentally validated, but it also has disadvantages such as the large influence of key word choice and the arbitrary nature of the areas covered by current literature. The second approach of finding miR targets using multiple algorithms is more objective and genome wide (advantage), but the results are not always accompanied by experimental validation (disadvantage). The third approach of finding miRs with correlated changes in expression with a target gene is also objective and genome wide (advantage), but the results largely depend on the datasets used and do not usually provide any information on the mechanism of correlated changes (disadvantage). Although the results obtained through each approach may have limited value for identifying feasible candidates, the miRs detected by multiple approaches should be of particular interest.</p><p>The members of the miR-183-96-182 cluster were detected by all three approaches. First, these miRs are enriched in the abstracts related to cancer EMT studies (<xref ref-type="table" rid="t1-cin-15-2016-091">Table 1</xref>). Second, miR-182 was among the top-ranking miRs predicted to target <italic>RECK</italic> by all the algorithms used. miR-96 was also predicted to target <italic>RECK</italic>, albeit at lower ranking (<xref ref-type="table" rid="t2-cin-15-2016-091">Table 2</xref>). Third, miR-183, miR-96, and miR-182 were among the top-ranking miRs with inverse correlation with <italic>RECK</italic> in our PDC test (<xref ref-type="table" rid="t3-cin-15-2016-091">Table 3</xref>). Indeed, Hirata et al already showed that miR-182 could suppress RECK expression in cell lines derived from bladder cancer<xref rid="b38-cin-15-2016-091" ref-type="bibr">38</xref> and prostate cancer.<xref rid="b39-cin-15-2016-091" ref-type="bibr">39</xref> Multiple studies also indicate that miR-96 targets <italic>RECK</italic>.<xref rid="b30-cin-15-2016-091" ref-type="bibr">30</xref>&#8211;<xref rid="b32-cin-15-2016-091" ref-type="bibr">32</xref></p><p>Several findings suggest the causative role of miR-183-96-182 in cancer EMT. Yang et al found that overexpression of miR-182 enhanced cell proliferation, invasion, and migration and induced molecular features of EMT, including upregulation of Snail and Vimentin with concomitant downregulation of E-cadherin.<xref rid="b43-cin-15-2016-091" ref-type="bibr">43</xref> In a recent study, the three members of miR-183-96-182 cluster were found to promote EMT in breast cancer cells.<xref rid="b44-cin-15-2016-091" ref-type="bibr">44</xref> However, multiple lines of evidence place miR-183-96-182 downstream of EMT as well. In gallbladder cancer cells, TGF&#946; was found to induce miR-182 expression, and inhibition of miR-182 resulted in suppression of TGF&#946;-induced cancer cell migration and invasion.<xref rid="b45-cin-15-2016-091" ref-type="bibr">45</xref> Although TGF&#946; is not equivalent to EMT, it is commonly used to induce EMT in cultured cells. Likewise, glioma cells treated with TGF&#946; showed remarkable increase in the expression of miR-182, miR-183, and miR-96.<xref rid="b46-cin-15-2016-091" ref-type="bibr">46</xref> Taken together, these reports suggest a positive feedback loop between EMT and miR-183-96-182 in cancer cells. Interestingly, TGF&#946; showed no effect on miR-182 expression in normal human astrocytes,<xref rid="b46-cin-15-2016-091" ref-type="bibr">46</xref> supporting the idea that miR-182 may be involved in cancer-specific inhibition of RECK induction after EMT. Further strengthening this idea, miR-182 was downregulated after EMT in a prostate epithelial cell line (noncancerous).<xref rid="b47-cin-15-2016-091" ref-type="bibr">47</xref> However, this study was categorized into &#8220;cancer EMT&#8221; (<xref ref-type="table" rid="t1-cin-15-2016-091">Table 1</xref>) because the abstract contains the terms &#8220;cancer&#8221; and &#8220;metastasis&#8221;, exemplifying a potential pitfall in such text-mining approaches.</p><p>miR-183-96-182 or its components are overexpressed in various cancers and may play positive roles in carcinogenesis.<xref rid="b43-cin-15-2016-091" ref-type="bibr">43</xref>,<xref rid="b44-cin-15-2016-091" ref-type="bibr">44</xref>,<xref rid="b48-cin-15-2016-091" ref-type="bibr">48</xref>&#8211;<xref rid="b51-cin-15-2016-091" ref-type="bibr">51</xref> Higher expression of the miR-183-96-182 cluster (as a whole or in part) in breast cancer cell lines compared with the MCF10A human breast epithelial cell line has also been reported in multiple studies.<xref rid="b27-cin-15-2016-091" ref-type="bibr">27</xref>,<xref rid="b32-cin-15-2016-091" ref-type="bibr">32</xref> However, there are several studies reporting a inverse correlation between miR-183-96-182 or its components and malignancy,<xref rid="b52-cin-15-2016-091" ref-type="bibr">52</xref>,<xref rid="b53-cin-15-2016-091" ref-type="bibr">53</xref> suggesting context-dependency of their actions.</p></sec><sec><title>Possible regulators of miR-183-96-182 expression</title><p>Several molecules such as &#946;-catenin/TCF/LEF,<xref rid="b54-cin-15-2016-091" ref-type="bibr">54</xref> p53,<xref rid="b55-cin-15-2016-091" ref-type="bibr">55</xref> and TGF&#946;<xref rid="b46-cin-15-2016-091" ref-type="bibr">46</xref> have been implicated in the regulation of miR-183-96-182 expression.<xref rid="b48-cin-15-2016-091" ref-type="bibr">48</xref> In this study, however, we found some evidence suggesting SOX2 and TEAD4 as potential regulators of miR-183-96-182 expression.</p><p>SOX2 seems to have multiple effects on carcinogenesis: in lung cancer, SOX2 expression has been correlated with better prognosis,<xref rid="b56-cin-15-2016-091" ref-type="bibr">56</xref>,<xref rid="b57-cin-15-2016-091" ref-type="bibr">57</xref> while in esophageal cancer, SOX2 amplification and/or overexpression has been associated with poorer prognosis.<xref rid="b58-cin-15-2016-091" ref-type="bibr">58</xref> In breast cancer, high SOX2 expression has been associated with cancer formation and malignancy.<xref rid="b59-cin-15-2016-091" ref-type="bibr">59</xref>&#8211;<xref rid="b61-cin-15-2016-091" ref-type="bibr">61</xref> From three datasets on SOX2 knockdown experiments, we found evidence supporting the model that SOX2 suppresses RECK expression via upregulation of miR-183-96-182 in cancer cells (<xref ref-type="fig" rid="f4-cin-15-2016-091">Fig. 4</xref>). Through a meta-analysis of two sets of SOX2 chromatin immunoprecipitation data using human embryonic stem cells, Vencken et al.<xref rid="b29-cin-15-2016-091" ref-type="bibr">29</xref> suggested a SOX2-binding site at &#8764;4 kb upstream of the predicted miR-183 TSS (<xref ref-type="fig" rid="f3-cin-15-2016-091">Fig. 3A</xref>); in that study, however, SOX2 was considered to be an inhibitor of EMT during embryonic development. In the context of cancer, however, SOX2 has been reported to bind to the promoters of <italic>SNAIL</italic>, <italic>SLUG</italic>, and <italic>TWIST</italic> and to promote EMT,<xref rid="b62-cin-15-2016-091" ref-type="bibr">62</xref> which fits with our model. Induction of Sox2 by TGF-&#946; has also been reported.<xref rid="b63-cin-15-2016-091" ref-type="bibr">63</xref> Thus, although multiple lines of evidence in the databases support the involvement of SOX2 in the pathway proposed here (<xref ref-type="fig" rid="f4-cin-15-2016-091">Fig. 4</xref>), the evidence is fragmentary and not always in comparable contexts.</p><p>TEAD4, a member of the TEAD family, plays crucial roles in mammalian development and carcinogenesis and is overexpressed in various types of cancer (<xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Fig. 4</xref>). Knockdown of TEAD4 in C2C12 cells resulted in marked upregulation of <italic>Reck</italic> expression (<xref ref-type="fig" rid="f3-cin-15-2016-091">Fig. 3D</xref>). Based on ENCODE ChIP-seq data, the nearest TEAD4-binding site is quite distant in the case of <italic>RECK</italic> (27.8 kb upstream of TSS) but very close in the case of miR-183-96-182 (0.2 kb upstream of TSS) (<xref ref-type="fig" rid="f3-cin-15-2016-091">Fig. 3A</xref>). In ovarian cancer, increased TEAD4 expression predicts poorer prognosis, and increased expression of both YAP and TEAD4 shows even more dramatic association with poor prognosis.<xref rid="b64-cin-15-2016-091" ref-type="bibr">64</xref> While this article was under revision, Liu et al published a study reporting TEAD4 overexpression in colorectal cancer and its activity to promote EMT by activating Vimentin expression.<xref rid="b65-cin-15-2016-091" ref-type="bibr">65</xref> Herein, we suggest that RECK inhibition via miR-183-96-182 activation may also be involved in TEAD4-induced malignant behaviors of cancer cells after EMT (<xref ref-type="fig" rid="f4-cin-15-2016-091">Fig. 4</xref>).</p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Through multiple <italic>in silico</italic> approaches, we aimed to narrow down the candidate miRs possibly involved in cancer-specific suppression of EMT-induced RECK upregulation. Two oncomiRs (miR-182 and miR-96) closely clustered on human chromosome 7 show inverse correlation in expression with <italic>RECK</italic>, are capable of directly targeting <italic>RECK</italic>, and have previously been implicated both upstream and downstream of EMT in cancer cells. We also predict that transcription factors such as SOX2 and TEAD4 may enhance the expression of the miR-183-96-182 cluster from which miR-182 and miR-96 are produced (<xref ref-type="fig" rid="f4-cin-15-2016-091">Fig. 4</xref>).</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank all LMCR members, especially Drs. Masakazu Toi, Satoru Ikeda, Kazuki Matsui, Yoshiteru Murofushi, Shun Ikeda, Nobuhiro Okada, and Boban Stanojevic, for their support and valuable discussion; Drs. Ryo Yamada and J. B. Brown for their instructions on some of the statistical and mathematical methods; and Takeshi Yamasaki and Kaori Sugiyama for administrative assistance.</p></ack><fn-group><fn id="fn1-cin-15-2016-091"><p><bold>ACADEMIC EDITOR:</bold> J. T. Efird, Editor in Chief</p></fn><fn id="fn2-cin-15-2016-091"><p><bold>PEER REVIEW:</bold> Four peer reviewers contributed to the peer review report. Reviewers&#8217; reports totaled 1,601 words, excluding any confidential comments to the academic editor.</p></fn><fn id="fn3-cin-15-2016-091"><p><bold>FUNDING:</bold> Authors disclose no external funding sources.</p></fn><fn id="fn4-cin-15-2016-091"><p><bold>COMPETING INTERESTS:</bold> Authors disclose no potential conflicts of interest.</p></fn><fn id="fn5-cin-15-2016-091"><p>Paper subject to independent expert blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).</p></fn><fn id="fn6-cin-15-2016-091"><p><bold>Author Contributions</bold></p><p>Conceived and designed the experiments: ZW, MN. Analyzed the data: ZW, RM. Wrote the first draft of the manuscript: ZW. Contributed to the writing of the manuscript: MN, RM, KY, YY. Developed the structure and arguments for the paper: ZW, MN. Made critical revisions and approved the final version: MN. All the authors reviewed and approved the final manuscript.</p></fn></fn-group><sec sec-type="supplementary-materials"><title>Supplementary Materials</title><supplementary-material content-type="local-data" id="s1-cin-15-2016-091"><caption><p><bold>Supplementary Figure 1</bold>. Genomic location of 5 probes for <italic>RECK</italic> in AgilentG4502A_07.</p><p><bold>Supplementary Figure 2</bold>. Scatter plot of top 36 miRs positively correlated with <italic>RECK</italic> in paired TCGA breast cancer samples.</p><p><bold>Supplementary Figure 3</bold>. Scatter plot of top 36 miRs inversely correlated with <italic>RECK</italic> in paired TCGA breast cancer samples.</p><p><bold>Supplementary Figure 4</bold>. ONCOMINE profile of transcription factors that might bind to miR-183-96-182 promoter.</p><p><bold>Supplementary Figure 5</bold>. Effect of EZH2 suppression on <italic>RECK</italic> and miR-183-96-182 cluster expression.</p><p><bold>Supplementary Table 1</bold>. miRs reported in cancer vs. non-cancer EMT studies.</p><p><bold>Supplementary Table 2</bold>. miRanda prediction of miRs that target <italic>RECK</italic>.</p><p><bold>Supplementary Table 3</bold>. TargetScan prediction of miRs that target <italic>RECK</italic>.</p><p><bold>Supplementary Table 4</bold>. PicTar prediction of miRs that target <italic>RECK</italic>.</p><p><bold>Supplementary Table 5</bold>. MicroT-CDS prediction of miRs that target <italic>RECK</italic>.</p><p><bold>Supplementary Table 6</bold>. miRs that positively or inversely correlated with <italic>RECK</italic> based on analysis of TCGA paired breast cancer dataset.</p></caption><media xlink:href="CIN-15-2016-091-s001.zip" mimetype="application" mime-subtype="x-zip-compressed" xlink:type="simple" id="d36e923" position="anchor"/></supplementary-material></sec><ref-list><title>REFERENCES</title><ref id="b1-cin-15-2016-091"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>C</given-names></name><name><surname>Sheng</surname><given-names>Z</given-names></name><name><surname>Horan</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><issue>22</issue><fpage>13221</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9789069</pub-id></element-citation></ref><ref id="b2-cin-15-2016-091"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Oh</surname><given-names>J</given-names></name><name><surname>Takahashi</surname><given-names>R</given-names></name><name><surname>Kondo</surname><given-names>S</given-names></name><name><surname>Kitayama</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>C</given-names></name></person-group><article-title>RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling</article-title><source>Cancer Metastasis Rev</source><year>2003</year><volume>22</volume><issue>2&#8211;3</issue><fpage>167</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">12784995</pub-id></element-citation></ref><ref id="b3-cin-15-2016-091"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>JC</given-names></name><name><surname>Thomas</surname><given-names>DM</given-names></name><name><surname>Choong</surname><given-names>PF</given-names></name><name><surname>Dass</surname><given-names>CR</given-names></name></person-group><article-title>RECK: a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer</article-title><source>Cancer Metastasis Rev</source><year>2007</year><volume>26</volume><issue>3&#8211;4</issue><fpage>675</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">17828469</pub-id></element-citation></ref><ref id="b4-cin-15-2016-091"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>C</given-names></name></person-group><article-title>Recklessness as a hallmark of aggressive cancer</article-title><source>Cancer Sci</source><year>2007</year><volume>98</volume><issue>11</issue><fpage>1659</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">17725805</pub-id></element-citation></ref><ref id="b5-cin-15-2016-091"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>C</given-names></name><name><surname>Matsuzaki</surname><given-names>T</given-names></name><name><surname>Kitayama</surname><given-names>H</given-names></name></person-group><article-title>What we learn from transformation suppressor genes: lessons from RECK</article-title><source>Future Oncol</source><year>2010</year><volume>6</volume><issue>7</issue><fpage>1105</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">20624123</pub-id></element-citation></ref><ref id="b6-cin-15-2016-091"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits</article-title><source>Nat Rev Cancer</source><year>2009</year><volume>9</volume><issue>4</issue><fpage>265</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">19262571</pub-id></element-citation></ref><ref id="b7-cin-15-2016-091"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamouille</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><article-title>Molecular mechanisms of epithelial-mesenchymal transition</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><issue>3</issue><fpage>178</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">24556840</pub-id></element-citation></ref><ref id="b8-cin-15-2016-091"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Leva</surname><given-names>G</given-names></name><name><surname>Garofalo</surname><given-names>M</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name></person-group><article-title>MicroRNAs in cancer</article-title><source>Annu Rev Pathol</source><year>2014</year><volume>9</volume><fpage>287</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">24079833</pub-id></element-citation></ref><ref id="b9-cin-15-2016-091"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuki</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Inagaki</surname><given-names>R</given-names></name><name><surname>Hiai</surname><given-names>H</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name></person-group><article-title>E-cadherin-downregulation and RECK-upregulation are coupled in the non-malignant epithelial cell line MCF10A but not in multiple carcinoma-derived cell lines</article-title><source>Sci Rep</source><year>2014</year><volume>4</volume><fpage>4568</fpage><pub-id pub-id-type="pmid">24691523</pub-id></element-citation></ref><ref id="b10-cin-15-2016-091"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rani</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>AB</given-names></name><name><surname>Ramachandran</surname><given-names>S</given-names></name></person-group><article-title>pubmed.mineR: an R package with text-mining algorithms to analyse PubMed abstracts</article-title><source>J Biosci</source><year>2015</year><volume>40</volume><issue>4</issue><fpage>671</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">26564970</pub-id></element-citation></ref><ref id="b11-cin-15-2016-091"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>KA</given-names></name><name><surname>Yates</surname><given-names>B</given-names></name><name><surname>Seal</surname><given-names>RL</given-names></name><name><surname>Wright</surname><given-names>MW</given-names></name><name><surname>Bruford</surname><given-names>EA</given-names></name></person-group><article-title><ext-link ext-link-type="uri" xlink:href="http://Genenames.org">Genenames.org</ext-link>: the HGNC resources in 2015</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><issue>Database issue</issue><fpage>D1079</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">25361968</pub-id></element-citation></ref><ref id="b12-cin-15-2016-091"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betel</surname><given-names>D</given-names></name><name><surname>Wilson</surname><given-names>M</given-names></name><name><surname>Gabow</surname><given-names>A</given-names></name><name><surname>Marks</surname><given-names>DS</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name></person-group><article-title>The <ext-link ext-link-type="uri" xlink:href="http://microRNA.org">microRNA.org</ext-link> resource: targets and expression</article-title><source>Nucleic Acids Res</source><year>2008</year><volume>36</volume><issue>Database issue</issue><fpage>D149</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">18158296</pub-id></element-citation></ref><ref id="b13-cin-15-2016-091"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betel</surname><given-names>D</given-names></name><name><surname>Koppal</surname><given-names>A</given-names></name><name><surname>Agius</surname><given-names>P</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Leslie</surname><given-names>C</given-names></name></person-group><article-title>Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites</article-title><source>Genome Biol</source><year>2010</year><volume>11</volume><issue>8</issue><fpage>R90</fpage><pub-id pub-id-type="pmid">20799968</pub-id></element-citation></ref><ref id="b14-cin-15-2016-091"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krek</surname><given-names>A</given-names></name><name><surname>Gr&#252;n</surname><given-names>D</given-names></name><name><surname>Poy</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Combinatorial microRNA target predictions</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><issue>5</issue><fpage>495</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">15806104</pub-id></element-citation></ref><ref id="b15-cin-15-2016-091"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimson</surname><given-names>A</given-names></name><name><surname>Farh</surname><given-names>KK</given-names></name><name><surname>Johnston</surname><given-names>WK</given-names></name><name><surname>Garrett-Engele</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>LP</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>MicroRNA targeting specificity in mammals: determinants beyond seed pairing</article-title><source>Mol Cell</source><year>2007</year><volume>27</volume><issue>1</issue><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">17612493</pub-id></element-citation></ref><ref id="b16-cin-15-2016-091"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>RC</given-names></name><name><surname>Farh</surname><given-names>KK</given-names></name><name><surname>Burge</surname><given-names>CB</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>Most mammalian mRNAs are conserved targets of microRNAs</article-title><source>Genome Res</source><year>2009</year><volume>19</volume><issue>1</issue><fpage>92</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">18955434</pub-id></element-citation></ref><ref id="b17-cin-15-2016-091"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>DM</given-names></name><name><surname>Baek</surname><given-names>D</given-names></name><name><surname>Shin</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>GW</given-names></name><name><surname>Grimson</surname><given-names>A</given-names></name><name><surname>Bartel</surname><given-names>DP</given-names></name></person-group><article-title>Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs</article-title><source>Nat Struct Mol Biol</source><year>2011</year><volume>18</volume><issue>10</issue><fpage>1139</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">21909094</pub-id></element-citation></ref><ref id="b18-cin-15-2016-091"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paraskevopoulou</surname><given-names>MD</given-names></name><name><surname>Georgakilas</surname><given-names>G</given-names></name><name><surname>Kostoulas</surname><given-names>N</given-names></name><etal/></person-group><article-title>DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><issue>Web Server issue</issue><fpage>W169</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">23680784</pub-id></element-citation></ref><ref id="b19-cin-15-2016-091"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Network</collab></person-group><article-title>Comprehensive molecular portraits of human breast tumours</article-title><source>Nature</source><year>2012</year><volume>490</volume><issue>7418</issue><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">23000897</pub-id></element-citation></ref><ref id="b20-cin-15-2016-091"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>WJ</given-names></name><name><surname>Sugnet</surname><given-names>CW</given-names></name><name><surname>Furey</surname><given-names>TS</given-names></name><etal/></person-group><article-title>The human genome browser at UCSC</article-title><source>Genome Res</source><year>2002</year><volume>12</volume><issue>6</issue><fpage>996</fpage><lpage>1006</lpage><pub-id pub-id-type="pmid">12045153</pub-id></element-citation></ref><ref id="b21-cin-15-2016-091"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbloom</surname><given-names>KR</given-names></name><name><surname>Sloan</surname><given-names>CA</given-names></name><name><surname>Malladi</surname><given-names>VS</given-names></name><etal/></person-group><article-title>ENCODE data in the UCSC genome browser: year 5 update</article-title><source>Nucleic Acids Res</source><year>2013</year><volume>41</volume><issue>Database issue</issue><fpage>D56</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">23193274</pub-id></element-citation></ref><ref id="b22-cin-15-2016-091"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name></person-group><article-title>GEOquery: a bridge between the gene expression omnibus (GEO) and BioConductor</article-title><source>Bioinformatics</source><year>2007</year><volume>23</volume><issue>14</issue><fpage>1846</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17496320</pub-id></element-citation></ref><ref id="b23-cin-15-2016-091"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Shanker</surname><given-names>K</given-names></name><etal/></person-group><article-title>ONCOMINE: a cancer microarray database and integrated data-mining platform</article-title><source>Neoplasia</source><year>2004</year><volume>6</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15068665</pub-id></element-citation></ref><ref id="b24-cin-15-2016-091"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Witkos</surname><given-names>TM</given-names></name><name><surname>Koscianska</surname><given-names>E</given-names></name><name><surname>Krzyzosiak</surname><given-names>WJ</given-names></name></person-group><article-title>Practical aspects of microRNA target prediction</article-title><source>Curr Mol Med</source><year>2011</year><volume>11</volume><issue>2</issue><fpage>93</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">21342132</pub-id></element-citation></ref><ref id="b25-cin-15-2016-091"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Tumor-suppressive function of miR-139-5p in esophageal squamous cell carcinoma</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>10</issue><fpage>e77068</fpage><pub-id pub-id-type="pmid">24204738</pub-id></element-citation></ref><ref id="b26-cin-15-2016-091"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>HK</given-names></name><name><surname>Tan</surname><given-names>AL</given-names></name><name><surname>Das</surname><given-names>K</given-names></name><etal/></person-group><article-title>Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><issue>9</issue><fpage>2657</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">21415212</pub-id></element-citation></ref><ref id="b27-cin-15-2016-091"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Sheng</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><etal/></person-group><article-title>MiR-183/-96/-182 cluster is up-regulated in most breast cancers and increases cell proliferation and migration</article-title><source>Breast Cancer Res</source><year>2014</year><volume>16</volume><issue>6</issue><fpage>473</fpage><pub-id pub-id-type="pmid">25394902</pub-id></element-citation></ref><ref id="b28-cin-15-2016-091"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>CH</given-names></name><name><surname>Sun</surname><given-names>YM</given-names></name><name><surname>Chang</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Identifying transcriptional start sites of human microRNAs based on high-throughput sequencing data</article-title><source>Nucleic Acids Res</source><year>2011</year><volume>39</volume><issue>21</issue><fpage>9345</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">21821656</pub-id></element-citation></ref><ref id="b29-cin-15-2016-091"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vencken</surname><given-names>SF</given-names></name><name><surname>Sethupathy</surname><given-names>P</given-names></name><name><surname>Blackshields</surname><given-names>G</given-names></name><etal/></person-group><article-title>An integrated analysis of the SOX2 microRNA response program in human pluripotent and nullipotent stem cell lines</article-title><source>BMC Genomics</source><year>2014</year><volume>15</volume><fpage>711</fpage><pub-id pub-id-type="pmid">25156079</pub-id></element-citation></ref><ref id="b30-cin-15-2016-091"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>MiR-96 downregulates RECK to promote growth and motility of non-small cell lung cancer cells</article-title><source>Mol Cell Biochem</source><year>2014</year><volume>390</volume><issue>1&#8211;2</issue><fpage>155</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">24469470</pub-id></element-citation></ref><ref id="b31-cin-15-2016-091"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name></person-group><article-title>MiR-96 promotes proliferation and chemo- or radioresistance by down-regulating RECK in esophageal cancer</article-title><source>Biomed Pharmacother</source><year>2014</year><volume>68</volume><issue>8</issue><fpage>951</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25465153</pub-id></element-citation></ref><ref id="b32-cin-15-2016-091"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>miR-96 promotes tumor proliferation and invasion by targeting RECK in breast cancer</article-title><source>Oncol Rep</source><year>2014</year><volume>31</volume><issue>3</issue><fpage>1357</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">24366472</pub-id></element-citation></ref><ref id="b33-cin-15-2016-091"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>KR</given-names></name><name><surname>Reis</surname><given-names>ST</given-names></name><name><surname>Viana</surname><given-names>N</given-names></name><etal/></person-group><article-title>Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer</article-title><source>J Cancer</source><year>2015</year><volume>6</volume><issue>3</issue><fpage>292</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">25663948</pub-id></element-citation></ref><ref id="b34-cin-15-2016-091"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><etal/></person-group><article-title>miR-21 plays a pivotal role in gastric cancer pathogenesis and progression</article-title><source>Lab Invest</source><year>2008</year><volume>88</volume><issue>12</issue><fpage>1358</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">18794849</pub-id></element-citation></ref><ref id="b35-cin-15-2016-091"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name></person-group><article-title>MiR-21 overexpression improves osteoporosis by targeting RECK</article-title><source>Mol Cell Biochem</source><year>2015</year><volume>405</volume><issue>1&#8211;2</issue><fpage>125</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">25893734</pub-id></element-citation></ref><ref id="b36-cin-15-2016-091"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>HM</given-names></name><name><surname>Phillips</surname><given-names>BL</given-names></name><name><surname>Patel</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing cysteine-rich protein with kazal motifs (RECK) in oral cancer</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><issue>35</issue><fpage>29261</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">22761427</pub-id></element-citation></ref><ref id="b37-cin-15-2016-091"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>CH</given-names></name><name><surname>Hou</surname><given-names>MF</given-names></name><name><surname>Hung</surname><given-names>WC</given-names></name></person-group><article-title>Up-regulation of miR-182 by &#946;-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor RECK</article-title><source>Biochem Biophys Acta</source><year>2013</year><volume>1830</volume><issue>4</issue><fpage>3067</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">23333633</pub-id></element-citation></ref><ref id="b38-cin-15-2016-091"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H</given-names></name><name><surname>Ueno</surname><given-names>K</given-names></name><name><surname>Shahryari</surname><given-names>V</given-names></name><etal/></person-group><article-title>Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>11</issue><fpage>e51056</fpage><pub-id pub-id-type="pmid">23226455</pub-id></element-citation></ref><ref id="b39-cin-15-2016-091"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>H</given-names></name><name><surname>Ueno</surname><given-names>K</given-names></name><name><surname>Shahryari</surname><given-names>V</given-names></name><etal/></person-group><article-title>MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>1</issue><fpage>e55502</fpage><pub-id pub-id-type="pmid">23383207</pub-id></element-citation></ref><ref id="b40-cin-15-2016-091"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name></person-group><article-title>Inhibition of miR-92b suppresses nonsmall cell lung cancer cells growth and motility by targeting RECK</article-title><source>Mol Cell Biochem</source><year>2014</year><volume>387</volume><issue>1&#8211;2</issue><fpage>171</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">24162673</pub-id></element-citation></ref><ref id="b41-cin-15-2016-091"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><article-title>microRNA-200b and microRNA-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs</article-title><source>RNA Biol</source><year>2015</year><volume>12</volume><issue>3</issue><fpage>276</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">25826661</pub-id></element-citation></ref><ref id="b42-cin-15-2016-091"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>S</given-names></name><name><surname>Izaurralde</surname><given-names>E</given-names></name></person-group><article-title>Towards a molecular understanding of microRNA-mediated gene silencing</article-title><source>Nat Rev Genet</source><year>2015</year><volume>16</volume><issue>7</issue><fpage>421</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">26077373</pub-id></element-citation></ref><ref id="b43-cin-15-2016-091"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>MH</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>WL</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>YQ</given-names></name></person-group><article-title>microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis</article-title><source>J Transl Med</source><year>2014</year><volume>12</volume><fpage>109</fpage><pub-id pub-id-type="pmid">24884732</pub-id></element-citation></ref><ref id="b44-cin-15-2016-091"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Qian</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Autocrine/paracrine human growth hormone-stimulated MicroRNA 96-182-183 cluster promotes epithelial-mesenchymal transition and invasion in breast cancer</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><issue>22</issue><fpage>13812</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">25873390</pub-id></element-citation></ref><ref id="b45-cin-15-2016-091"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Kan</surname><given-names>T</given-names></name><etal/></person-group><article-title>TGF-&#946; upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1</article-title><source>Mol Biosyst</source><year>2014</year><volume>10</volume><issue>3</issue><fpage>679</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">24445397</pub-id></element-citation></ref><ref id="b46-cin-15-2016-091"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>TGF-&#946; induces miR-182 to sustain NF-&#954;B activation in glioma subsets</article-title><source>J Clin Invest</source><year>2012</year><volume>122</volume><issue>10</issue><fpage>3563</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">23006329</pub-id></element-citation></ref><ref id="b47-cin-15-2016-091"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>WC</given-names></name><name><surname>Hellem</surname><given-names>MR</given-names></name><etal/></person-group><article-title>MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells</article-title><source>Int J Cancer</source><year>2013</year><volume>133</volume><issue>3</issue><fpage>544</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">23354685</pub-id></element-citation></ref><ref id="b48-cin-15-2016-091"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dambal</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>M</given-names></name><name><surname>Mihelich</surname><given-names>B</given-names></name><name><surname>Nonn</surname><given-names>L</given-names></name></person-group><article-title>The microRNA-183 cluster: the family that plays together stays together</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><issue>15</issue><fpage>7173</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">26170234</pub-id></element-citation></ref><ref id="b49-cin-15-2016-091"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ress</surname><given-names>AL</given-names></name><name><surname>Stiegelbauer</surname><given-names>V</given-names></name><name><surname>Winter</surname><given-names>E</given-names></name><etal/></person-group><article-title>MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients</article-title><source>Mol Carcinog</source><year>2015</year><volume>54</volume><issue>11</issue><fpage>1442</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">25256312</pub-id></element-citation></ref><ref id="b50-cin-15-2016-091"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YY</given-names></name><name><surname>Zheng</surname><given-names>JY</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>CL</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name></person-group><article-title>miR-183 induces cell proliferation, migration, and invasion by regulating PDCD4 expression in the SW1990 pancreatic cancer cell line</article-title><source>Biomed Pharmacother</source><year>2015</year><volume>70</volume><fpage>151</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">25776494</pub-id></element-citation></ref><ref id="b51-cin-15-2016-091"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weeraratne</surname><given-names>SD</given-names></name><name><surname>Amani</surname><given-names>V</given-names></name><name><surname>Teider</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pleiotropic effects of miR-183&#8764;96&#8764;182 converge to regulate cell survival, proliferation and migration in medulloblastoma</article-title><source>Acta Neuropathol</source><year>2012</year><volume>123</volume><issue>4</issue><fpage>539</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">22402744</pub-id></element-citation></ref><ref id="b52-cin-15-2016-091"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XL</given-names></name><name><surname>Hara</surname><given-names>T</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183-96-182 cluster</article-title><source>Mol Cell Biol</source><year>2014</year><volume>34</volume><issue>3</issue><fpage>533</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">24277930</pub-id></element-citation></ref><ref id="b53-cin-15-2016-091"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kundu</surname><given-names>ST</given-names></name><name><surname>Byers</surname><given-names>LA</given-names></name><name><surname>Peng</surname><given-names>DH</given-names></name><etal/></person-group><article-title>The miR-200 family and the miR-183&#8764;96&#8764;182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers</article-title><source>Oncogene</source><year>2016</year><volume>35</volume><issue>2</issue><fpage>173</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">25798833</pub-id></element-citation></ref><ref id="b54-cin-15-2016-091"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the beta-Catenin/TCF/LEF-1 pathway in gastric cancer cells</article-title><source>Nucleic Acids Res</source><year>2014</year><volume>42</volume><issue>5</issue><fpage>2988</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">24335145</pub-id></element-citation></ref><ref id="b55-cin-15-2016-091"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>CJ</given-names></name><name><surname>Chao</surname><given-names>CH</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><etal/></person-group><article-title>p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs</article-title><source>Nat Cell Biol</source><year>2011</year><volume>13</volume><issue>3</issue><fpage>317</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">21336307</pub-id></element-citation></ref><ref id="b56-cin-15-2016-091"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilbertz</surname><given-names>T</given-names></name><name><surname>Wagner</surname><given-names>P</given-names></name><name><surname>Petersen</surname><given-names>K</given-names></name><etal/></person-group><article-title>SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer</article-title><source>Mod Pathol</source><year>2011</year><volume>24</volume><issue>7</issue><fpage>944</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">21460799</pub-id></element-citation></ref><ref id="b57-cin-15-2016-091"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velcheti</surname><given-names>V</given-names></name><name><surname>Schalper</surname><given-names>K</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><etal/></person-group><article-title>High SOX2 levels predict better outcome in non-small cell lung carcinomas</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>4</issue><fpage>e61427</fpage><pub-id pub-id-type="pmid">23620753</pub-id></element-citation></ref><ref id="b58-cin-15-2016-091"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forghanifard</surname><given-names>MM</given-names></name><name><surname>Ardalan Khales</surname><given-names>S</given-names></name><name><surname>Javdani-Mallak</surname><given-names>A</given-names></name><name><surname>Rad</surname><given-names>A</given-names></name><name><surname>Farshchian</surname><given-names>M</given-names></name><name><surname>Abbaszadegan</surname><given-names>MR</given-names></name></person-group><article-title>Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma</article-title><source>Med Oncol</source><year>2014</year><volume>31</volume><issue>4</issue><fpage>922</fpage><pub-id pub-id-type="pmid">24659265</pub-id></element-citation></ref><ref id="b59-cin-15-2016-091"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>26</issue><fpage>17969</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">18456656</pub-id></element-citation></ref><ref id="b60-cin-15-2016-091"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lengerke</surname><given-names>C</given-names></name><name><surname>Fehm</surname><given-names>T</given-names></name><name><surname>Kurth</surname><given-names>R</given-names></name><etal/></person-group><article-title>Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma</article-title><source>BMC Cancer</source><year>2011</year><volume>11</volume><fpage>42</fpage><pub-id pub-id-type="pmid">21276239</pub-id></element-citation></ref><ref id="b61-cin-15-2016-091"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stolzenburg</surname><given-names>S</given-names></name><name><surname>Rots</surname><given-names>MG</given-names></name><name><surname>Beltran</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><issue>14</issue><fpage>6725</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">22561374</pub-id></element-citation></ref><ref id="b62-cin-15-2016-091"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herreros-Villanueva</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>JS</given-names></name><name><surname>Koenig</surname><given-names>A</given-names></name><etal/></person-group><article-title>SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells</article-title><source>Oncogenesis</source><year>2013</year><volume>2</volume><fpage>e61</fpage><pub-id pub-id-type="pmid">23917223</pub-id></element-citation></ref><ref id="b63-cin-15-2016-091"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikushima</surname><given-names>H</given-names></name><name><surname>Todo</surname><given-names>T</given-names></name><name><surname>Ino</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Miyazawa</surname><given-names>K</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name></person-group><article-title>Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors</article-title><source>Cell Stem Cell</source><year>2009</year><volume>5</volume><issue>5</issue><fpage>504</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">19896441</pub-id></element-citation></ref><ref id="b64-cin-15-2016-091"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>3</issue><fpage>e91770</fpage><pub-id pub-id-type="pmid">24622501</pub-id></element-citation></ref><ref id="b65-cin-15-2016-091"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner</article-title><source>Oncogene</source><year>2015</year><comment>Epub ahead of print</comment><pub-id pub-id-type="doi">10.1038/onc.2015.342</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-cin-15-2016-091" position="float"><label>Figure 1</label><caption><p>Algorithm of paired data correlation (PDC) test.</p></caption><graphic xlink:href="cin-15-2016-091f1"/></fig><fig id="f2-cin-15-2016-091" position="float"><label>Figure 2</label><caption><p>PDC test for <italic>RECK</italic> mRNA and various miRs in paired TCGA breast cancer samples. (A) Expression of <italic>RECK</italic> mRNA in 53 pairs of cancer and matched normal tissues in TCGA breast cancer dataset. The boxes indicate the interquartile range (IQR) of data between 75% (Q3) and 25% (Q1). The bars below and above each box indicate the data in Q1 &#8722; 1.5 &#215; IQR and Q3 + 1.5 &#215; IQR, respectively. <italic>P</italic>-value was calculated by paired <italic>t</italic>-test. (B) Ratio (in log<sub>2</sub>) of the <italic>RECK</italic> mRNA levels between cancer and normal tissues from 53 breast cancer patients. Blue and red broken lines indicate the cutoff values for &#8220;Down&#8221; (0.8) and &#8220;Up&#8221; (1.25) groups, respectively. (C) Median of ratios (in log<sub>2</sub>) of the levels of miRs (1046 species) among 53 pairs of cancer and normal tissues. Blue and red broken lines indicate the cutoff values for &#8220;Down&#8221; (0.5) and &#8220;Up&#8221; (2.0) groups, respectively. (D) Distribution of diff.sum based on random shuffling of original miRs diff matrix and then generating a 1000 times larger simulated dataset (see &#8220;Methods&#8221; section for details). (E) Relationship between the levels (in log<sub>2</sub>) of <italic>RECK</italic> mRNA and various miRs. Top row: miRs with low diff.sum scores (positive correlation). Middle row: miRs with intermediate diff.sum scores. Bottom row: miRs with high diff.sum scores (inverse correlation). Red spots represent cancer samples and blue spots represent normal tissue samples. Gray line represents regression curve. <italic>P</italic> represents the cumulative probability obtained from the distribution showed in (D), and values sufficiently close to 0 or 1 both indicate a rare event. For more completed scatter between top miRs with low/high diff.sum scores and <italic>RECK</italic> mRNA, see <xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Figures 2</xref> and <xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">3</xref>.</p></caption><graphic xlink:href="cin-15-2016-091f2"/></fig><fig id="f3-cin-15-2016-091" position="float"><label>Figure 3</label><caption><p>Candidates for the transcription factors regulating the miR-183-96-182 cluster. (A) The 23-kb human genomic region containing the miR-183-96-182 cluster as shown in the UCSC genome browser. Three miRs, SOX2, and TEAD4 are highlighted by red boxes. MYC and EZH2 are underlined. The binding site for SOX2 is based on Vencken&#8217;s meta-analysis (PMID: 25156079). TSS of pri-miR-183-96-182 is based on Chien et al (PMID: 21821656). (B) Effects of TEAD4 knockdown (KD) on the level of <italic>Reck</italic> mRNA in differentiated C2C12 cells. ShSC, control shRNA; ShA and ShB, two independent shRNAs targeting TEAD4; <italic>n</italic> = 1. (C) Effects of SOX2 KD on the levels of miR-182, miR-96, and <italic>RECK</italic> mRNA in undifferentiated human embryonic stem cells. WT, treated with scrambled siRNA; SOX2 KD, treated with SOX2 siRNA; <italic>n</italic> = 1. (D) Effects of knocking down SOX2 or <italic>RMST</italic> on the level of <italic>RECK</italic> mRNA in neural stem cells. si-NT, control siRNA; si-RMST and si-SOX2, siRNA targeting <italic>RMST</italic> and SOX2, respectively; <italic>n</italic> = 1. (B), (C), and (D) are based on the following NCBI GEO datasets, respectively, GSE27845, GSE67993, and GSE49403.</p></caption><graphic xlink:href="cin-15-2016-091f3"/></fig><fig id="f4-cin-15-2016-091" position="float"><label>Figure 4</label><caption><p>Model consistent with our findings. In cancer cells, transcription factors such as SOX2 and TEAD4 are upregulated and induce miR-182-96-183 expression. Three miRs in turn promote EMT, while two of them (miR-182 and miR-96) target <italic>RECK</italic> mRNA. The positive feedback loop between EMT and miR-182-96-183 works to stably downregulate RECK after EMT.</p></caption><graphic xlink:href="cin-15-2016-091f4"/></fig><table-wrap id="t1-cin-15-2016-091" position="float"><label>Table 1</label><caption><p>Number of original research papers describing miRs in the context of cancer and/or noncancer EMT.</p></caption><table-wrap-foot><fn id="tfn1-cin-15-2016-091"><p><bold>Notes:</bold> The numbers in parentheses indicate their proportion to all papers describing cancer EMT (second column) or noncancer EMT (third column). Ratio: ratio between the proportions (the numbers in the parentheses). <italic>P</italic>-value: probability calculated using two-tailed prop.test for null hypothesis that [proportion in cancer EMT] = [proportion in noncancer EMT]. The top miRs in each of the following four categories are listed: (1) enriched in cancer EMT, (2) enriched in both cancer and noncancer EMT, (3) enriched in noncancer EMT, and (4) members of the miR-183-96-182 cluster (individually and in total). For full results, see <xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Table 1</xref>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-cin-15-2016-091" position="float"><label>Table 2</label><caption><p><italic>RECK</italic>-targeting miRs predicted by four commonly used algorithms.</p></caption><table-wrap-foot><fn id="tfn2-cin-15-2016-091"><p><bold>Notes:</bold> miRs with a mirSVR score smaller than &#8722;1.2 and members of miR-183-96-182 are shown. For full lists, see <xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Tables 2</xref><xref ref-type="supplementary-material" rid="s1-cin-15-2016-091"/><xref ref-type="supplementary-material" rid="s1-cin-15-2016-091"/>&#8211;<xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">5</xref>. Lower values predict higher probabilities of <italic>RECK</italic>-targeting in the case of mirSVR (miRanda) and Context score (TargetScan), while higher scores predict higher probabilities in the case of PicRar score, miTG score (MicroT-CDS), and <italic>P</italic><sub>CT</sub> (TargetScan).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-cin-15-2016-091" position="float"><label>Table 3</label><caption><p>miRs exhibiting positive or inverse correlation in expression with <italic>RECK</italic> mRNA among the matched breast cancer and normal breast tissues from 53 patients (TCGA data).</p></caption><table-wrap-foot><fn id="tfn3-cin-15-2016-091"><p><bold>Notes:</bold> Representative references are cited (PMID). Ranking: T, from top; B, from bottom. <italic>P</italic> represents the cumulative probability. For full list, see <xref ref-type="supplementary-material" rid="s1-cin-15-2016-091">Supplementary Table 6</xref>.</p></fn></table-wrap-foot></table-wrap></floats-group></article>